Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

BACKGROUND: Biologically distinct subtypes of diffuse large B-cell lymphoma can be identified using gene-expression analysis to determine their cell of origin, corresponding to germinal centre or activated B cell. We aimed to investigate whether adding bortezomib to standard therapy could improve ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Andrew, Cummin, Thomas E, Barrans, Sharon, Maishman, Tom, Mamot, Christoph, Novak, Urban, Caddy, Josh, Stanton, Louise, Kazmi-Stokes, Shamim, McMillan, Andrew, Fields, Paul, Pocock, Christopher, Collins, Graham P, Stephens, Richard, Cucco, Francesco, Clipson, Alexandra, Sha, Chulin, Tooze, Reuben, Care, Matthew A, Griffiths, Gareth, Du, Ming-Qing, Westhead, David R, Burton, Catherine, Johnson, Peter W M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494978/
https://www.ncbi.nlm.nih.gov/pubmed/30948276
http://dx.doi.org/10.1016/S1470-2045(18)30935-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494978/
https://www.ncbi.nlm.nih.gov/pubmed/30948276
http://dx.doi.org/10.1016/S1470-2045(18)30935-5

Ejemplares similares